PRC
RVNC

Pearl River Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Pearl River Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$2K – 850
2018
Q4 		$2K Buy
+100
New +$2.2K 0.01% 793

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Pearl River Capital's RVNC Position: Q1 2019 in Review

Pearl River Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2019, closing a stake of 100 shares — an estimated $2K sold.

Pearl River Capital first reported a position in RVNC in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 112 funds tracked by Wall St. Rank hold RVNC as of Q1 2019.

  • Pearl River Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 100 Revance Therapeutics, Inc. shares in Q1 2019, an estimated $2K.
  • Pearl River Capital first reported a position in Revance Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Revance Therapeutics, Inc. position peaked at $2K in Q4 2018.
  • 112 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.